Etanercept
Also known as: AMG 073, Benepali, Enbrel, Erelzi, Etanercept, Eticovo, TNFR:Fc, TNFR2-Fc
Source Etanercept at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Etanercept is a recombinant fusion protein administered subcutaneously to treat several autoimmune disorders by neutralizing tumor necrosis factor.
Mechanism of Action
Soluble dimeric fusion of the extracellular domain of the human TNF receptor 2 linked to the Fc portion of IgG1; binds circulating TNF‑α and TNF‑β, preventing their interaction with cell‑surface TNF receptors and thereby reducing inflammatory signaling.
Routes of Administration
Goals & Uses
- Hidradenitis suppurativaAutoimmune DiseaseModerate
- Ankylosing spondylitisAutoimmune DiseaseHigh
- Management of psoriatic arthritisInflammatory/AutoimmuneHigh
- Treatment of plaque psoriasisDermatologyHigh
- Plaque psoriasisDermatologyHigh
- Psoriatic arthritisAutoimmune DiseaseHigh
- Rheumatoid arthritisAutoimmune DiseaseHigh
- Treatment of juvenile idiopathic arthritis (JIA)Pediatric RheumatologyHigh
- Treatment of ankylosing spondylitisInflammatory/AutoimmuneHigh
- Prevention of radiographic joint damageInflammatory/AutoimmuneHigh
- Reduction of signs and symptoms of rheumatoid arthritisInflammatory/AutoimmuneHigh
Contraindications
- Hypersensitivity to etanercept or any componentAllergyModerate
- Active serious infections (including sepsis)Infectious DiseaseHigh
- Moderate-to-severe heart failure (NYHA class III/IV)CardiovascularHigh
- Systemic lupus erythematosusAutoimmuneModerate
- Active serious infectionInfectionHigh
- Active tuberculosisInfectiousHigh
- Active hepatitis B infectionInfectious DiseaseHigh
- SepsisInfectionHigh
- Hypersensitivity to etanercept or excipientsAllergyHigh
Adverse Effects
- Malignancies (e.g., lymphoma)OncologicRare
- Serious infections (e.g., bacterial, fungal)InfectionUncommon
- Injection site reactionsLocalCommon
- Serious infections (bacterial, opportunistic, fungal)Infectious DiseaseUncommon
- Malignancy (lymphoma, solid tumors)OncologyRare
- Demyelinating disordersNeurologicalRare
- Tuberculosis reactivationInfectious DiseaseUncommon
- Upper respiratory infectionsInfectiousCommon
- Demyelinating diseaseNeurologicRare
- Upper respiratory tract infectionInfectiousCommon
- Serious infectionsInfectiousUncommon
- Upper respiratory tract infectionsInfectious DiseaseCommon
- Malignancies (lymphoma, skin cancer)NeoplasmRare
Drug Interactions
- Other immunosuppressants (e.g., methotrexate)Moderate
- AnakinraHigh
- Live vaccinesHigh
- CyclophosphamideModerate
- Cytokine‑targeted therapies (e.g., anakinra)Moderate
- SulfasalazineModerate
- Other immunosuppressants (e.g., methotrexate, azathioprine)Moderate
- AbataceptHigh
- MethotrexateLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with latent tuberculosis (untreated)Infectious DiseaseAbsolute
- ElderlyAgeRelative
- Pediatric patients (≥2 years)AgeRelative
- Immunocompromised patientsImmunologicRelative
- Elderly (≥65 years)GeriatricRelative
- Pediatrics (<2 years)AgeAbsolute
- BreastfeedingReproductiveRelative
- Pediatric patients <2 yearsAgeAbsolute
Regulatory Status
- European UnionApprovedApproved: Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasisEMA approval 1999.
- United StatesApprovedApproved: Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasisFDA approved 1998.
- United KingdomApprovedApproved: Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasisMHRA approved; same as EU.
Approved as a biologic DMARD; biosimilar versions (e.g., etanercept‑ykro, etanercept‑szzs) have received regulatory approval in multiple regions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Etanercept?
Etanercept is a recombinant fusion protein administered subcutaneously to treat several autoimmune disorders by neutralizing tumor necrosis factor.
What is Etanercept used for?
Etanercept is educationally associated with: Hidradenitis suppurativa, Ankylosing spondylitis, Management of psoriatic arthritis, Treatment of plaque psoriasis, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Treatment of juvenile idiopathic arthritis (JIA), Treatment of ankylosing spondylitis, Prevention of radiographic joint damage, Reduction of signs and symptoms of rheumatoid arthritis. Educational only — not medical advice.
How is Etanercept administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Etanercept?
Reported adverse effects include: Malignancies (e.g., lymphoma), Serious infections (e.g., bacterial, fungal), Injection site reactions, Serious infections (bacterial, opportunistic, fungal), Malignancy (lymphoma, solid tumors), Demyelinating disorders, Tuberculosis reactivation, Upper respiratory infections, Demyelinating disease, Upper respiratory tract infection, Serious infections, Upper respiratory tract infections, Malignancies (lymphoma, skin cancer). This list is not exhaustive — consult a qualified clinician.
Who should avoid Etanercept?
Recorded contraindications: Hypersensitivity to etanercept or any component, Active serious infections (including sepsis), Moderate-to-severe heart failure (NYHA class III/IV), Systemic lupus erythematosus, Active serious infection, Active tuberculosis, Active hepatitis B infection, Sepsis, Hypersensitivity to etanercept or excipients. Consult a qualified clinician before use.